Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Ignyta
January 02, 2018
Pharma news over the Christmas period 2018
December 22, 2017
Ignyta investors have the last laugh
November 14, 2017
Loxo’s Bayer deal falls short of bullish expectations
October 19, 2017
World Lung – Spectrum shoots for another lung cancer niche
October 18, 2017
World Lung – Ignyta’s chance to make up lost ground on Loxo
October 12, 2017
Lung cancer focus – drugging the undruggable KRAS
October 11, 2017
World Lung and SITC – two more doses of oncology
July 10, 2017
Strong small cap performance drives second-quarter gains
June 08, 2017
Asco event analyser – Puma investors’ Aphinity for Roche data
June 03, 2017
Asco – Loxo nudges ahead of Ignyta with tumour-agnostic therapy
January 24, 2017
Vantage point – Life for kinase inhibitors in an immuno-oncology world
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 17, 2023
PD(L)anner – February 2023
February 09, 2023
Biopharma and Medtech Review 2022
Editor's Picks
March 13, 2023
Silicon Valley Bank: biopharma’s latest crisis
March 13, 2023
Pfizer rescues biotech
February 28, 2023
Why Pfizer (and others) will be interested in Seagen
March 04, 2023
ACC 2023 – Esperion’s outcomes win looks lacklustre
March 06, 2023
T-cell receptor behemoths consolidate? Not quite
